SLC22A29 Activators
Solute carrier family 22 member 29 (Slc22a29) is a predicted transporter with anion:anion antiporter, short-chain fatty acid transmembrane transporter, and sodium-independent organic anion transmembrane transporter activities. Located in the basolateral plasma membrane, it plays a crucial role in organic anion transport, being expressed in various tissues such as the embryo, liver, metanephros, and testis. The activation of Slc22a29 involves both direct and indirect mechanisms. Direct activators, such as butyrate, diclofenac, and Propionic acid, directly serve as substrates for the organic anion antiporter activity, enhancing Slc22a29-mediated transport of short-chain and medium-chain fatty acids across the basolateral plasma membrane.
Indirect activators, like probenecid, clofibrate, and naproxen, modulate related pathways or cellular processes. Probenecid indirectly activates Slc22a29 by inhibiting competing transporters, enhancing substrate availability. Octanoic acid, by modulating lipid metabolism, indirectly up-regulates Slc22a29's short-chain fatty acid transmembrane transporter activity. Naproxen, as an NSAID, directly serves as a substrate, stimulating Slc22a29-mediated organic anion transport. Understanding Slc22a29's activation sheds light on its role in the transport of various organic anions and fatty acids across cellular membranes. The interconnected regulatory networks, including substrate availability and lipid metabolism, showcase the sophisticated nature of Slc22a29's regulation within cellular contexts. Further exploration into these mechanisms will contribute to a comprehensive understanding of Slc22a29's role in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Butyrate, a short-chain fatty acid, directly activates Slc22a29 by serving as a substrate for the organic anion antiporter activity. As a transporter substrate, butyrate enhances Slc22a29-mediated short-chain fatty acid transport across the basolateral plasma membrane, up-regulating the transporter's activity. | ||||||
Diclofenac acid | 15307-86-5 | sc-357332 sc-357332A | 5 g 25 g | $109.00 $298.00 | 5 | |
Diclofenac, an NSAID, directly activates Slc22a29 as a sodium-independent organic anion substrate. By serving as a substrate, diclofenac stimulates Slc22a29-mediated organic anion transport, contributing to increased transport activity across the basolateral plasma membrane. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Probenecid, an organic anion transporter inhibitor, indirectly activates Slc22a29. Inhibition of competing transporters, such as OATs, enhances the availability of substrates for Slc22a29, indirectly up-regulating its organic anion antiporter and short-chain fatty acid transmembrane transporter activity. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, an antimetabolite and antifolate drug, directly activates Slc22a29 as a sodium-independent organic anion substrate. By serving as a substrate, methotrexate stimulates Slc22a29-mediated organic anion transport, contributing to increased transport activity across the basolateral plasma membrane. | ||||||
Pyruvic acid | 127-17-3 | sc-208191 sc-208191A | 25 g 100 g | $41.00 $96.00 | ||
Pyruvic acid, an alpha-keto acid, directly activates Slc22a29 as a sodium-independent organic anion substrate. By serving as a substrate, pyruvic acid stimulates Slc22a29-mediated organic anion transport, contributing to increased transport activity across the basolateral plasma membrane. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin, an NSAID, directly activates Slc22a29 as a sodium-independent organic anion substrate. By serving as a substrate, indomethacin stimulates Slc22a29-mediated organic anion transport, contributing to increased transport activity across the basolateral plasma membrane. | ||||||
Benzoic acid | 65-85-0 | sc-203317 sc-203317A sc-203317B | 25 g 100 g 500 g | $20.00 $51.00 $61.00 | ||
Benzoic acid, a common food preservative, directly activates Slc22a29 by serving as a substrate for the organic anion antiporter activity. Acting as a transporter substrate, benzoic acid enhances Slc22a29-mediated benzoic acid transport across the basolateral plasma membrane, up-regulating the transporter's activity. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate, a lipid-lowering drug, indirectly activates Slc22a29. By modulating lipid metabolism, clofibrate enhances the availability of fatty acid substrates for Slc22a29, indirectly up-regulating its short-chain fatty acid transmembrane transporter activity and contributing to increased transport across the plasma membrane. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $41.00 | ||
Naproxen, an NSAID, directly activates Slc22a29 as a sodium-independent organic anion substrate. By serving as a substrate, naproxen stimulates Slc22a29-mediated organic anion transport, contributing to increased transport activity across the basolateral plasma membrane. | ||||||